Aumolertinib showed substantial clinical benefits as adjuvant therapy in Chinese patients with stage II–IIIB EGFR-mutated NSCLC. The manageable safety profile of aumolertinib supports its suitability in the adjuvant setting.
[Articles] Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
The Lancet Oncology | | Liang Zhang, Xiqin Zhang, Lin Wu, Wenqun Xing, Chunling Liu, Peng Zhang, Kai Chen, Jianhua Shi, Shidong Xu, Xiaodong Zhang, Xiaorong Dong, Haohui Fang, Xinmin Yu, Yang Gao, Gaofeng Li, Zhenming Chen, Shaonan Fan, Xiaoqing Zhang, Ying Cheng
Topics: lung-cancer, skin-cancer, blood-cancer, clinical-trials